Roche

(IN BRIEF) Roche’s ongoing Phase Ib/IIa Brainshuttle™ AD study of trontinemab shows that 91 percent of participants reach amyloid PET negativity, with ARIA‑E rates under 5 percent. The company has outlined Phase III TRONTIER 1 and 2 trials in early symptomatic Alzheimer’s for 2025, plus a planned … Read the full press release →

(IN BRIEF) Pfizer and BioNTech have received a positive recommendation from the EMA’s CHMP for their LP.8.1-adapted monovalent COVID-19 vaccine, COMIRNATY® LP.8.1, for individuals aged six months and older. This updated vaccine offers improved immune protection against prevalent SARS-CoV-2 subvariants, … Read the full press release →

(IN BRIEF) Novartis has appointed Mukul Mehta as CFO and Executive Committee member effective March 16, 2026. He will replace long‑time CFO Harry Kirsch, who retires on March 15, 2026, after 22 years at the company. Kirsch oversaw major strategic … Read the full press release →

(IN BRIEF) The University of Liverpool has launched the Liverpool Interdisciplinary Neuroscience Centre (LINC), an ambitious collaboration uniting nearly 170 researchers and clinicians from the University, The Walton Centre NHS Foundation Trust, Brain Health Northwest, and global partners. LINC aims … Read the full press release →

(IN BRIEF) Roche has revealed that Dr. Hans Clevers, Head of Pharma Research and Early Development and board member since 2019, will retire from his pRED role at the end of August, though he will continue leading the Institute of … Read the full press release →

(IN BRIEF) Roche presented positive phase I/II data for NXT007, its Chugai-engineered bispecific antibody for haemophilia A, at the 2025 ISTH Congress. In the NXTAGE study’s highest-dose cohorts (B-3 and B-4), none of the 30 participants experienced bleeds requiring treatment, … Read the full press release →

(IN BRIEF) BioNTech agreed to buy CureVac in an all-stock deal valuing CureVac at ~$1.25 billion, exchanging each share for $5.46 in BioNTech ADSs—a 55% premium to its recent stock price. The merger, expected to close in 2025, strengthens BioNTech’s … Read the full press release →

(IN BRIEF) Roche announced the European Commission’s approval of a label extension for Evrysdi® (risdiplam) to include a new 5mg tablet, offering a room-temperature stable alternative to the original oral solution for individuals with spinal muscular atrophy (SMA). The tablet, … Read the full press release →

(IN BRIEF) Roche presented promising 96-week data from the Phase II FENopta study, showing that its investigational drug, fenebrutinib, significantly reduced relapse rates and prevented disability progression in patients with relapsing multiple sclerosis (RMS). The study revealed an annualized relapse … Read the full press release →

(IN BRIEF) The Vienna Stock Exchange has expanded its global market offering by allowing the trading of all stocks in the Swiss Market Index (SMI), which includes leading companies like Nestlé, Novartis, Roche, and UBS. This follows the Swiss Federal … Read the full press release →